Oxford BioMedica plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Frank Mathias
- Full Time Employees
- 986
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Windrush Court Oxford OXF United Kingdom OX4 6LT
- IPO Date
- Nov 15, 1996
- Website
- oxb.com
- Similar Companies
- Business
- Oxford Biomedica plc (OXB.L) is a global contract development and manufacturing organization (CDMO) specializing in viral vectors for cell and gene therapies; it provides end-to-end services from plasmid design and process development to clinical and commercial GMP manufacturing of lentiviral vectors via its LentiVector platform and TetraVecta system, adeno-associated virus (AAV) vectors through its inAAVate and dual-plasmid systems, adenoviral vectors, and other viral vector types including suspension and perfusion processes with stable producer cell lines; additional offerings encompass procurement and storage services, analytical methods, quality assurance, and regulatory support for pharmaceutical and biotechnology clients targeting oncology, ophthalmology, CNS disorders, and other diseases. Founded in 1996 and headquartered in Oxford, UK, the company operates development and manufacturing facilities in Oxfordshire, UK; Lyon and Strasbourg, France; Bedford, Massachusetts; and Durham, North Carolina, US, serving a global customer base with over 30 years of experience as a pioneer in the sector. Recent developments include the October 2025 acquisition of a commercial-scale, FDA-approved viral vector facility in Durham, North Carolina from Resilience for $4.5 million to expand US GMP capacity in AAV and fill-finish services; completion of the June 2025 purchase of the remaining 10% stake in US subsidiary OXB US LLC from Q32 Bio, achieving 100% ownership; an August 2025 equity placing raising approximately £60 million to fund US expansion and process improvements; and a new four-year term loan facility of up to $125 million with Oaktree Capital Management, drawing $60 million to refinance prior debt and support growth.
Company News
Oxford Biomedica H1 Earnings Call Highlights
Oxford Biomedica (LON:OXB) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?
Connecting Excellence CEO on first acquisition and Bitcoin strategy
Oxford Biomedica (LON:OXB) Shares Pass Below Two Hundred Day Moving Average – What’s Next?
OXB Capital Markets Event
Oxford Biomedica (LON:OXB) Shares Pass Below 200 Day Moving Average – What’s Next?
OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture
Oxford Biomedica (LON:OXB) Stock Crosses Below 200 Day Moving Average – Here’s Why
Oxford Biomedica H2 Earnings Call Highlights
OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards
Preliminary results for the year ended 31 December 2025
Oxford Biomedica (LON:OXB) Stock Price Passes Below 200-Day Moving Average – Here’s What Happened
Oxford Biomedica (LON:OXB) Shares Pass Below 200 Day Moving Average – Should You Sell?
OXB announces date for Capital Markets Day and participation in upcoming investor conferences
Full year Trading Update and Notice of Results